Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 322.0
(0.0%)
JPY 322.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 7 Billion JPY | -28.03% |
| 2021 | 9.73 Billion JPY | 8.39% |
| 2020 | 8.97 Billion JPY | 47.16% |
| 2019 | 6.09 Billion JPY | 48.24% |
| 2018 | 4.11 Billion JPY | 1.52% |
| 2017 | 4.05 Billion JPY | 19.06% |
| 2016 | 3.4 Billion JPY | 7.47% |
| 2015 | 3.16 Billion JPY | -48.29% |
| 2014 | 6.12 Billion JPY | 17.43% |
| 2013 | 5.21 Billion JPY | 47.43% |
| 2012 | 3.53 Billion JPY | 1.74% |
| 2011 | 3.47 Billion JPY | 17.48% |
| 2010 | 2.96 Billion JPY | -10.71% |
| 2009 | 3.31 Billion JPY | 33.89% |
| 2008 | 2.47 Billion JPY | 21.13% |
| 2007 | 2.04 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 6.46 Billion JPY | -1.36% |
| 2023 Q1 | 6.54 Billion JPY | -6.48% |
| 2023 Q3 | 6.05 Billion JPY | -6.33% |
| 2022 Q1 | 8.6 Billion JPY | -11.6% |
| 2022 FY | 7 Billion JPY | -28.03% |
| 2022 Q4 | 7 Billion JPY | 5.21% |
| 2022 Q3 | 6.65 Billion JPY | -8.08% |
| 2022 Q2 | 7.24 Billion JPY | -15.81% |
| 2021 Q2 | 7.22 Billion JPY | 8.39% |
| 2021 Q4 | 9.73 Billion JPY | 19.96% |
| 2021 Q3 | 8.11 Billion JPY | 12.26% |
| 2021 FY | 9.73 Billion JPY | 8.39% |
| 2021 Q1 | 6.66 Billion JPY | 0.0% |
| 2020 Q2 | 6.53 Billion JPY | 7.15% |
| 2020 FY | 8.97 Billion JPY | 47.16% |
| 2020 Q1 | 6.09 Billion JPY | 12.96% |
| 2020 Q3 | 7.68 Billion JPY | 17.62% |
| 2019 FY | 6.09 Billion JPY | 48.24% |
| 2019 Q1 | 4.11 Billion JPY | 22.91% |
| 2019 Q2 | 3.25 Billion JPY | -20.99% |
| 2019 Q4 | 5.39 Billion JPY | 54.24% |
| 2019 Q3 | 3.5 Billion JPY | 7.69% |
| 2018 FY | 4.11 Billion JPY | 1.52% |
| 2018 Q2 | 3.11 Billion JPY | -23.26% |
| 2018 Q1 | 4.05 Billion JPY | 26.52% |
| 2018 Q3 | 3.27 Billion JPY | 5.29% |
| 2018 Q4 | 3.34 Billion JPY | 2.22% |
| 2017 Q3 | 2.94 Billion JPY | 1.8% |
| 2017 FY | 4.05 Billion JPY | 19.06% |
| 2017 Q4 | 3.2 Billion JPY | 8.75% |
| 2017 Q2 | 2.89 Billion JPY | -15.0% |
| 2017 Q1 | 3.4 Billion JPY | 10.19% |
| 2016 Q4 | 3.08 Billion JPY | 16.52% |
| 2016 Q2 | 2.62 Billion JPY | -17.26% |
| 2016 Q3 | 2.65 Billion JPY | 1.17% |
| 2016 FY | 3.4 Billion JPY | 7.47% |
| 2016 Q1 | 3.16 Billion JPY | -24.7% |
| 2015 Q1 | 6.12 Billion JPY | 31.91% |
| 2015 Q4 | 4.2 Billion JPY | 6.86% |
| 2015 FY | 3.16 Billion JPY | -48.29% |
| 2015 Q2 | 2.89 Billion JPY | -52.74% |
| 2015 Q3 | 3.93 Billion JPY | 35.97% |
| 2014 Q2 | 5.04 Billion JPY | -3.37% |
| 2014 FY | 6.12 Billion JPY | 17.43% |
| 2014 Q3 | 3.42 Billion JPY | -31.99% |
| 2014 Q1 | 5.21 Billion JPY | 21.1% |
| 2014 Q4 | 4.64 Billion JPY | 35.46% |
| 2013 Q4 | 4.3 Billion JPY | 30.51% |
| 2013 Q1 | 3.53 Billion JPY | 15.8% |
| 2013 Q2 | 3.23 Billion JPY | -8.46% |
| 2013 FY | 5.21 Billion JPY | 47.43% |
| 2013 Q3 | 3.3 Billion JPY | 1.9% |
| 2012 FY | 3.53 Billion JPY | 1.74% |
| 2012 Q4 | 3.05 Billion JPY | 12.51% |
| 2012 Q3 | 2.71 Billion JPY | -11.88% |
| 2012 Q2 | 3.08 Billion JPY | -11.39% |
| 2012 Q1 | 3.47 Billion JPY | 28.12% |
| 2011 Q3 | 2.49 Billion JPY | -2.31% |
| 2011 Q4 | 2.71 Billion JPY | 8.88% |
| 2011 FY | 3.47 Billion JPY | 17.48% |
| 2011 Q2 | 2.55 Billion JPY | -13.79% |
| 2011 Q1 | 2.96 Billion JPY | 25.67% |
| 2010 FY | 2.96 Billion JPY | -10.71% |
| 2010 Q1 | 3.31 Billion JPY | -8.2% |
| 2010 Q2 | 2.13 Billion JPY | -35.51% |
| 2010 Q4 | 2.35 Billion JPY | 0.7% |
| 2010 Q3 | 2.33 Billion JPY | 9.41% |
| 2009 Q2 | 2.09 Billion JPY | -15.38% |
| 2009 Q3 | 3.25 Billion JPY | 55.18% |
| 2009 Q4 | 3.61 Billion JPY | 11.07% |
| 2009 Q1 | 2.47 Billion JPY | 0.0% |
| 2009 FY | 3.31 Billion JPY | 33.89% |
| 2008 FY | 2.47 Billion JPY | 21.13% |
| 2007 FY | 2.04 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 71.975% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.911% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.068% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 95.739% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -106.275% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 83.664% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 74.869% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 98.585% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -38.948% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 88.649% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 77.287% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 82.402% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 77.471% |
| Tsumura & Co. | 132.88 Billion JPY | 94.73% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 82.401% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 47.334% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 97.451% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 84.141% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 90.095% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 85.066% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 72.471% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 13.991% |
| MedRx Co., Ltd | 129 Million JPY | -5328.682% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -113.993% |
| Solasia Pharma K.K. | 673 Million JPY | -940.565% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -984.89% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 77.684% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 95.73% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -592.448% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 98.664% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -0.729% |